Literature DB >> 21810706

Population-based risk for complications after transthoracic needle lung biopsy of a pulmonary nodule: an analysis of discharge records.

Renda Soylemez Wiener1, Lisa M Schwartz, Steven Woloshin, H Gilbert Welch.   

Abstract

BACKGROUND: Because pulmonary nodules are found in up to 25% of patients undergoing computed tomography of the chest, the question of whether to perform biopsy is becoming increasingly common. Data on complications after transthoracic needle lung biopsy are limited to case series from selected institutions.
OBJECTIVE: To determine population-based estimates of risks for complications after transthoracic needle biopsy of a pulmonary nodule.
DESIGN: Cross-sectional analysis.
SETTING: The 2006 State Ambulatory Surgery Databases and State Inpatient Databases for California, Florida, Michigan, and New York from the Healthcare Cost and Utilization Project. PATIENTS: 15 865 adults who had transthoracic needle biopsy of a pulmonary nodule. MEASUREMENTS: Percentage of biopsies complicated by hemorrhage, any pneumothorax, or pneumothorax requiring a chest tube, and adjusted odds ratios for these complications associated with various biopsy characteristics, calculated by using multivariate, population-averaged generalized estimating equations.
RESULTS: Although hemorrhage was rare, complicating 1.0% (95% CI, 0.9% to 1.2%) of biopsies, 17.8% (CI, 11.8% to 23.8%) of patients with hemorrhage required a blood transfusion. In contrast, the risk for any pneumothorax was 15.0% (CI, 14.0% to 16.0%), and 6.6% (CI, 6.0% to 7.2%) of all biopsies resulted in pneumothorax requiring a chest tube. Compared with patients without complications, those who experienced hemorrhage or pneumothorax requiring a chest tube had longer lengths of stay (P < 0.001) and were more likely to develop respiratory failure requiring mechanical ventilation (P = 0.020). Patients aged 60 to 69 years (as opposed to younger or older patients), smokers, and those with chronic obstructive pulmonary disease had higher risk for complications. LIMITATIONS: Estimated risks may be inaccurate if coding of complications is incomplete. The analyzed databases contain little clinical detail (such as information on nodule characteristics or biopsy pathology) and cannot indicate whether performing the biopsy produced useful information.
CONCLUSION: Whereas hemorrhage is an infrequent complication of transthoracic needle lung biopsy, pneumothorax is common and often necessitates chest tube placement. These population-based data should help patients and physicians make more informed choices about whether to perform biopsy of a pulmonary nodule. PRIMARY FUNDING SOURCE: Department of Veterans Affairs and National Cancer Institute.

Entities:  

Mesh:

Year:  2011        PMID: 21810706      PMCID: PMC3150964          DOI: 10.7326/0003-4819-155-3-201108020-00003

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  18 in total

1.  Does clinical evidence support ICD-9-CM diagnosis coding of complications?

Authors:  E P McCarthy; L I Iezzoni; R B Davis; R H Palmer; M Cahalane; M B Hamel; K Mukamal; R S Phillips; D T Davies
Journal:  Med Care       Date:  2000-08       Impact factor: 2.983

2.  Identification of in-hospital complications from claims data. Is it valid?

Authors:  A G Lawthers; E P McCarthy; R B Davis; L E Peterson; R H Palmer; L I Iezzoni
Journal:  Med Care       Date:  2000-08       Impact factor: 2.983

Review 3.  Clinical practice. The solitary pulmonary nodule.

Authors:  David Ost; Alan M Fein; Steven H Feinsilver
Journal:  N Engl J Med       Date:  2003-06-19       Impact factor: 91.245

4.  Risk factors of pneumothorax and bleeding: multivariate analysis of 660 CT-guided coaxial cutting needle lung biopsies.

Authors:  Kee-Min Yeow; I-Hao Su; Kuang-Tse Pan; Pei-Kwei Tsay; Kar-Wai Lui; Yun-Chung Cheung; Andy Shau-Bin Chou
Journal:  Chest       Date:  2004-09       Impact factor: 9.410

5.  Cases of iatrogenic pneumothorax can be identified from ICD-9-CM coded data.

Authors:  Banafsheh Sadeghi; Ruth Baron; Patricia Zrelak; Garth H Utter; Jeffrey J Geppert; Daniel J Tancredi; Patrick S Romano
Journal:  Am J Med Qual       Date:  2010 May-Jun       Impact factor: 1.852

6.  On-site evaluation of percutaneous CT-guided fine needle aspiration of pulmonary lesions. A study of 321 cases.

Authors:  Ernesto Mazza; Cristina Maddau; Alessandro Ricciardi; Massimo Falchini; Marzia Matucci; Tommaso Ciarpallini
Journal:  Radiol Med       Date:  2005-09       Impact factor: 3.469

7.  Duration of pneumothorax as a complication of CT-guided lung biopsy.

Authors:  T Yamagami; T Kato; T Hirota; R Yoshimatsu; T Matsumoto; T Nishimura
Journal:  Australas Radiol       Date:  2006-10

8.  CT-guided transthoracic needle aspiration biopsy of pulmonary nodules: needle size and pneumothorax rate.

Authors:  Patricia R Geraghty; Stephen T Kee; Gillian McFarlane; Mahmood K Razavi; Daniel Y Sze; Michael D Dake
Journal:  Radiology       Date:  2003-11       Impact factor: 11.105

9.  CT guided percutaneous fine needle biopsy of small lung lesions in outpatients. Safety and efficacy of the procedure compared to inpatients.

Authors:  Maurizio Romano; Salvatore Griffo; Maria Gentile; Pier Paolo Mainenti; Oscar Tamburrini; Vittorio Iaccarino; Marco Salvatore
Journal:  Radiol Med       Date:  2004-09       Impact factor: 3.469

10.  Factors associated with pneumothorax and pneumothorax requiring treatment after percutaneous lung biopsy in 443 consecutive patients.

Authors:  Anne M Covey; Ripal Gandhi; Lynn A Brody; George Getrajdman; Howard T Thaler; Karen T Brown
Journal:  J Vasc Interv Radiol       Date:  2004-05       Impact factor: 3.464

View more
  145 in total

1.  Atrial fibrillation and pneumothorax after transthoracic needle lung biopsy.

Authors:  Alexander Liu; Iain Southern; Edward Nicol
Journal:  BMJ Case Rep       Date:  2012-01-18

2.  Meta-analysis of guided bronchoscopy for the evaluation of the pulmonary nodule.

Authors:  Jessica S Wang Memoli; Paul J Nietert; Gerard A Silvestri
Journal:  Chest       Date:  2012-08       Impact factor: 9.410

3.  Endoscopic Doppler optical coherence tomography and autofluorescence imaging of peripheral pulmonary nodules and vasculature.

Authors:  Hamid Pahlevaninezhad; Anthony M D Lee; Alexander Ritchie; Tawimas Shaipanich; Wei Zhang; Diana N Ionescu; Geoffrey Hohert; Calum MacAulay; Stephen Lam; Pierre Lane
Journal:  Biomed Opt Express       Date:  2015-09-30       Impact factor: 3.732

4.  Rapid needle-out patient-rollover approach after CT-guided lung biopsy: challenges and future directions.

Authors:  Ailbhe C O'Neill; Neasa Ní Mhuircheartaigh; Jonathan D Dodd
Journal:  J Thorac Dis       Date:  2015-10       Impact factor: 2.895

5.  Patient dose simulations for scanning-beam digital x-ray tomosynthesis of the lungs.

Authors:  Geoff Nelson; Sungwon Yoon; Ganesh Krishna; Brian Wilfley; Rebecca Fahrig
Journal:  Med Phys       Date:  2013-11       Impact factor: 4.071

6.  Quality Gaps and Comparative Effectiveness of Management Strategies for Recurrent Malignant Pleural Effusions.

Authors:  David E Ost; Jiangong Niu; Hui Zhao; Horiana B Grosu; Sharon H Giordano
Journal:  Chest       Date:  2017-08-31       Impact factor: 9.410

Review 7.  Lung cancer diagnosis and staging in the minimally invasive age with increasing demands for tissue analysis.

Authors:  Erik Folch; Daniel B Costa; Jeffrey Wright; Paul A VanderLaan
Journal:  Transl Lung Cancer Res       Date:  2015-08

8.  Complication Rates and Downstream Medical Costs Associated With Invasive Diagnostic Procedures for Lung Abnormalities in the Community Setting.

Authors:  Jinhai Huo; Ying Xu; Tommy Sheu; Robert J Volk; Ya-Chen Tina Shih
Journal:  JAMA Intern Med       Date:  2019-03-01       Impact factor: 21.873

9.  Tumor acquisition for biomarker research in lung cancer.

Authors:  Marvaretta Stevenson; Jared Christensen; Debra Shoemaker; Traci Foster; William T Barry; Betty C Tong; Momen Wahidi; Scott Shofer; Michael Datto; Geoffrey Ginsburg; Jeffrey Crawford; Thomas D'Amico; Neal Ready
Journal:  Cancer Invest       Date:  2014-05-09       Impact factor: 2.176

10.  Quality gaps and comparative effectiveness in lung cancer staging and diagnosis.

Authors:  David E Ost; Jiangong Niu; Linda S Elting; Thomas A Buchholz; Sharon H Giordano
Journal:  Chest       Date:  2014-02       Impact factor: 9.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.